offer therapeutic strategies to limit inflammation associated with multiple debilitating chronic human diseases.

References and Notes

- 1. D. A. Hill, D. Artis, Annu. Rev. Immunol. 28, 623 (2010). 2. L. V. Hooper, A. J. Macpherson, Nat. Rev. Immunol. 10,
- 159 (2010).
- R. E. Ley, D. A. Peterson, J. I. Gordon, *Cell* 124, 837 (2006).
- T. Obata et al., Proc. Natl. Acad. Sci. U.S.A. 107, 7419 (2010).
- 5. A. J. Macpherson, T. Uhr, Science 303, 1662 (2004).
- J. M. Brenchley, D. C. Douek, Annu. Rev. Immunol. 30, 149 (2012).
- 7. N. G. Sandler *et al.*, *Gastroenterology* **141**, 1220, 1230, e1 (2011).
- M. A. McGuckin, R. Eri, L. A. Simms, T. H. Florin, G. Radford-Smith, *Inflamm. Bowel Dis.* **15**, 100 (2009).
- 9. D. Lescut et al., Gastroenterol. Clin. Biol. 14, 811 (1990).
- 10. A. Parlesak, C. Schäfer, T. Schütz, J. C. Bode, C. Bode, *J. Hepatol.* **32**, 742 (2000).
- 11. G. F. Sonnenberg, L. A. Fouser, D. Artis, *Nat. Immunol.* 12, 383 (2011).
- 12. W. Ouyang, J. K. Kolls, Y. Zheng, *Immunity* **28**, 454 (2008).
- G. F. Sonnenberg, L. A. Monticelli, M. M. Elloso, L. A. Fouser, D. Artis, *Immunity* 34, 122 (2011).
- 14. H. Spits, T. Cupedo, Annu. Rev. Immunol. 30, 647 (2012).
- 15. D. A. Hill et al., Nat. Med. 18, 538 (2012).
- 16. Y. Zheng et al., Nat. Med. 14, 282 (2008).
- 17. S. J. Aujla et al., Nat. Med. 14, 275 (2008).
- 18. S. Vaishnava et al., Science **334**, 255 (2011).
- 19. E. Slack et al., Science **325**, 617 (2009).
- A. J. Macpherson, N. L. Harris, Nat. Rev. Immunol. 4, 478 (2004).
- 21. K. S. Bergstrom *et al.*, *PLoS Pathog.* 6, e1000902 (2010).
- G. Funke, D. Monnet, C. deBernardis, A. von Graevenitz, J. Freney, J. Clin. Microbiol. 36, 1948 (1998).
- H. J. Busse, A. Stolz, in *Prokaryotes*, M. E. A. Dworkin, Ed. (Springer, New York, 2006), pp. 675–700.
- 24. C. Ryckman *et al.*, *J. Immunol.* **169**, 3307 (2002).
- R. E. Ley, C. A. Lozupone, M. Hamady, R. Knight,
 J. I. Gordon, *Nat. Rev. Microbiol.* 6, 776 (2008).
- 26. G. Aisenberg, K. V. Rolston, A. Safdar, *Cancer* **101**, 2134 (2004).

- F. Espinoza-Gómez, O. A. Newton-Sánchez, V. Melnikov, O. Virgen-González, J. Unrau, *Braz. J. Infect. Dis.* 11, 603 (2007).
- J. M. Duggan, S. J. Goldstein, C. E. Chenoweth, C. A. Kauffman, S. F. Bradley, *Clin. Infect. Dis.* 23, 569 (1996).
- 29. L. Liu et al., J. Clin. Microbiol. 40, 1210 (2002).

Acknowledgments: We thank members of the Artis laboratory for discussions and critical reading of the manuscript. We also thank S. Olland, R. Zollner, K. Lam, and A. Root at Pfizer for the preparation of IL-22 cytokine and antibodies. The research is supported by the NIH (grants Al061570. AI087990, AI074878, AI083480, AI095466, and AI095608 to D.A.; T32-AI007532 to G.F.S and L.A.M.; T32-AI055428 to G.F.S.: T32-RR007063 and K08-DK093784 to T.A.: and AI47619 to K.-M.C.); the NIH-funded Penn Center for AIDS Research (grant P30 AI 045008 to G.F.S. and D.A.); the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award (to D.A.); the Philadelphia VA Medical Research and Merit Review and American Gastroenterological Association (to K.-M.C.); the Ministry of Education, Culture, Sports, Science and Technology of Japan (to J.K., N.S., and H.K); and the Program for Promotion of Basic and Applied Researches for Innovations in Bio-Oriented Industry (to].K.). We also thank the Matthew J. Ryan Veterinary Hospital Pathology Lab. the National Institute of Diabetes and Digestive and Kidney Disease Center for the Molecular Studies in Digestive and Liver Disease Molecular Pathology and Imaging Core (grant P30DK50306), the Penn Microarray Facility, and the Abramson Cancer Center Flow Cytometry and Cell Sorting Resource Laboratory [partially supported by National Cancer Institute (NCI) Comprehensive Cancer Center Support grant #2-P30 CA016520] for technical advice and support. Several human tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the NCI. The data presented in the paper are tabulated in the main paper and in the supplementary materials.

Supplementary Materials

www.sciencemag.org/cgi/content/full/336/6086/1321/DC1 Materials and Methods Figs. S1 to S12 Tables S1 and S2

Reference (30)

28 November 2011; accepted 24 April 2012 10.1126/science.1222551

Regulated Virulence Controls the Ability of a Pathogen to Compete with the Gut Microbiota

Nobuhiko Kamada,¹ Yun-Gi Kim,¹ Ho Pan Sham,² Bruce A. Vallance,² José L. Puente,³ Eric C. Martens,⁴ Gabriel Núñez¹*

The virulence mechanisms that allow pathogens to colonize the intestine remain unclear. Here, we show that germ-free animals are unable to eradicate *Citrobacter rodentium*, a model for human infections with attaching and effacing bacteria. Early in infection, virulence genes were expressed and required for pathogen growth in conventionally raised mice but not germ-free mice. Virulence gene expression was down-regulated during the late phase of infection, which led to relocation of the pathogen to the intestinal lumen where it was outcompeted by commensals. The ability of commensals to outcompete *C. rodentium* was determined, at least in part, by the capacity of the pathogen and commensals to grow on structurally similar carbohydrates. Thus, pathogen colonization is controlled by bacterial virulence and through competition with metabolically related commensals.

Enterohemorragic *Escherichia coli* (EHEC) and enteropathogenic *E. coli* (EPEC) are important causes of diarrhea and mortality worldwide (*1*, *2*). These Gram-negative bacteria attach to and colonize the intestinal tract by inducing attaching and effacing (AE) lesions on the intestinal epithelium (1, 2). The genomes of AE pathogens harbor the locus of enterocyte

inflammation, the adaptive immune system can limit the presence of live bacteria in the periphery. Collectively, these data suggest that ILCs are essential to promote anatomical containment of *Alcaligenes* to lymphoid tissues and limit the induction of systemic inflammation in lymphocytereplete hosts. Loss of containment of commensal bacteria and chronic systemic inflammation is associated

with several chronic human diseases (6-8). To determine whether these diseases were also associated with a loss of containment of Alcaligenes spp., we analyzed serum samples from cohorts of pediatric Crohn's disease patients or chronically hepatitis C virus (HCV)-infected adults for the presence of Alcaligenes-specific IgG. In comparison to age-matched controls, serum from pediatric Crohn's disease patients and plasma from cirrhotic HCV-infected individuals awaiting liver transplantation exhibited significantly elevated levels of relative IgG specific for Alcaligenes spp. (Fig. 4, I and J). Although further analysis of HCV-infected individuals with and without cirrhosis demonstrated no correlations between Alcaligenes-specific IgG levels and patient age or serum alanine transaminase (fig. S11, A and B), there were significant correlations between plasma levels of Alcaligenes-specific IgG and laboratory measures of liver disease, including increased serum bilirubin and international normalized ratio (INR) of prothrombin time as well as decreased serum albumin and platelets (Fig. 4, K to N).

Mammals have evolved multiple immunologic and physiologic mechanisms to promote the anatomical containment of commensal bacteria to intestinal sites, including promoting physical barriers (via epithelial cell tight junctions), biochemical barriers (via production of mucus layers and antimicrobial peptides), and immunologic barriers (via IgA-mediated immune exclusion; intraepithelial lymphocytes; and innate pathways involving phagocytosis, Toll-like receptor-mediated sensing, and oxidative bursts) (1, 2, 18, 19, 25). The demonstration that depletion of ILCs results in the selective dissemination and survival of Alcaligenes spp. in peripheral tissues of mice indicates that, in addition to established pathways that nonselectively maintain intestinal barrier function, more discriminatory processes may have evolved to promote the selective anatomical containment of phylogenetically defined communities of lymphoid-resident commensal bacteria (fig. S12). It is notable that Alcaligenes spp. has recently been identified as a dominant lymphoidresident commensal species colonizing the PPs and mLNs of mammals (4). Moreover, peripheral dissemination of Alcaligenes spp. has been reported in patients with HIV infection, cancer, and cystic fibrosis (26-29). The identification of a pathway through which IL-22-producing ILCs can prevent dissemination of lymphoid-resident Alcaligenes spp. and limit systemic inflammation highlights the selectivity of immune-mediated containment of defined commensal bacterial species and could

REPORTS

effacement (LEE) that is critical for these bacteria to colonize their hosts and cause pathology (3, 4). Infection with Citrobacter rodentium-a natural pathogen of mice that is used to model human infections with EPEC and EHEC (5, 6)—is associated with a significant but reversible decrease in the number of total commensals in the colon (7, 8). To assess the role of the microbiota in this enteric infection, germ-free (GF) and specific pathogen-free (SPF) C57BL/6 mice were orally inoculated with C. rodentium. The pathogen colonized the intestines of SPF mice, reaching maximal concentrations in the feces on days 7 to 10 post infection, followed by a decline by day 12, and becoming undetectable by day 22 (Fig. 1A). In contrast, GF mice harbored 10 times as much C. rodentium on days 7 to 10 post infection, and unlike SPF mice, they were unable to clear C. rodentium even by day 42 when the experiments were terminated (Fig. 1A). It was remarkable that all GF infected mice remained alive despite high and persistent pathogen burdens (Fig. 1B). Notably, the recruitment of neutrophils, inflammatory macrophages, and CD3⁺ T cells in response to infection was similar in SPF and GF mice (fig. S1). Consistently, histological analysis revealed comparable pathology scores on day 12 post infection, which declined on day 22 in both GF and SPF mice (fig. S1). Furthermore, expression of antimicrobial peptides including RegIIIy, β -defensin-1, β -defensin-3, and β -defensin-4 was comparable in the colons of infected SPF and GF mice (fig. S2).

The expression of most LEE genes in C. rodentium is controlled by Ler, a member of the H-NS protein family (3, 4, 9, 10). Ler was expressed in the feces on day 7 post infection in both GF and SPF mice (Fig. 2A). It was noteworthy that expression of ler and tir, a Ler-regulated gene, were both down-regulated on day 12 after infection in both GF and SPF mice and were not expressed at day 42 in GF mice, despite robust pathogen colonization (Fig. 2A and fig. S3). To monitor the expression of *ler* in the intestine, we engineered a bioluminescent reporter C. rodentium strain in which the ler promoter was fused to the luxCDABE operon of Photorhabdus luminescens (fig. S4) (11). Ler expression was detected in the feces on day 5, but down-regulated by days 7 to 12 post infection (Fig. 2B). Furthermore, ler expression was visualized on day 5 post infection in the ileum, cecum, and distal colon but was downregulated on day 14 in both SPF and GF mice (Fig. 2C). The ler luminescent signal in GF mice was ~ 10 times that in SPF mice, consistent with higher pathogen load in GF mice. If the *C. rodentium* were harvested from infected GF mice at day 21 and reinoculated into SPF mice, the pathogen robustly grew in the intestines and elicited colonic inflammation (fig. S5).

Because expression of virulence LEE genes is essential for pathogen colonization in the intestines of SPF mice (4), we asked whether LEE virulence was required for colonization in GF mice. To assess this, we orally infected GF and SPF mice with wild-type (WT) C. rodentium and isogenic strains deficient in Ler (Δler) or in EscN $(\Delta escN)$, a Ler-regulated adenosine triphosphatase required for injection of virulence factors via the type III secretion system (T3SS) into host cells (4). As expected, WT, but not the Δler or $\Delta escN$ strains, grew in the intestine of SPF mice (Fig. 2D). Notably, the Δler and $\Delta escN$ mutants grew robustly in GF mice, reaching numbers similar to those of the WT pathogen (Fig. 2D and fig. S6). Thus, Ler-dependent LEE virulence is not required for intestinal C. rodentium growth in the absence of the microbiota. To determine whether Ler and the T3SS regulate the ability of the microbiota to outcompete the pathogen, we orally infected GF mice with WT or the Δler or the $\Delta escN$ mutant C. rodentium, and the infected GF mice were colonized with commensals by cohousing them at either day 3 or day 21 post infection with SPF mice. Notably, the burden of WT C. rodentium in GF mice harboring the pathogen for 21 days declined significantly after 3 days of cohousing and was further reduced by 5 to 6 logs by day 7, similarly to the decline observed in mice infected with the Δler or the $\Delta escN$ mutant for 3 and 21 days (Fig. 2E and fig. S6). In contrast, the microbiota could not outcompete the WT bacterium on day 3 post infection when GF mice were cohoused with SPF mice (Fig. 2E), consistent with the observation that ler expression is active in WT C. rodentium at day 3 post infection (fig. S7).

C. rodentium induces marked inflammation in the distal colon, which requires LEE virulence factors including the T3SS (4). If the T3SS promotes outgrowth of C. rodentium by enabling the pathogen to colonize a niche at or near the epithelium, it would be expected that impaired colonization of the $\Delta escN$ mutant could not be rescued when inflammation is provided by other means. Oral administration of dextran sulfate sodium (DSS), a chemical that directly damages the colonic epithelium (12), enhanced the colonization of the WT bacterium by 3 logs but not that of the $\Delta escN$ mutant (fig. S8). In addition, coinfection of the $\Delta escN$ mutant with WT C. rodentium, which induces inflammation, did not rescue colonization by the T3SS mutant strain (fig. S8). These results indicate that inflammation promotes colonization of WT C. rodentium not in the absence of a functional T3SS. The adaptive immune system-including immunoglobulin G (IgG) production and T helper 17 responses against the pathogen-are important

for eradication of *C. rodentium* (13–16). It was noteworthy that the production of IgG, IgM, and IgA against *C. rodentium* was similar in GF and SPF mice (fig. S9). Furthermore, the generation of colonic interleukin-17 (IL-17)– and interferon- γ –producing T cells in response to *C. rodentium* was comparable in SPF and GF mice (fig. S10).

C. rodentium colonizes and infects the surface of the intestinal epithelium, a site largely devoid of commensals (17). At day 5 post infection, Tir, a marker of C. rodentium attachment to the epithelium, was seen on the intestinal surface of GF mice infected with WT C. rodentium, but not those with the Δler strain (fig. S11). In contrast, Tir labeling was not detected on day 21 post infection on the intestinal surface of mice infected with either WT or mutant C. rodentium (fig. S11). Consistently, the WT pathogen was associated with the epithelium, whereas the Δler mutant localized to the intestinal lumen on day 5 post infection as determined by dual-fluorescence in situ hybridization (FISH) (Fig. 3A). On day 21 post infection, however, neither WT nor Δler C. rodentium bacteria were detected on the epithelial surface; instead, they localized to the intestinal lumen (Fig. 3A). Similarly, transmission electron microscopy revealed C. rodentium at or near the intestinal epithelium on day 5, but not on day 21, post infection (Fig. 3B). As expected, $\Delta ler C.$ rodentium did not localize at or near the epithelium on day 5 post infection



Fig. 1. The microbiota is required for eradication of *C. rodentium*. (**A** and **B**) SPF and GF mice (n = 7) were infected orally with 1×10^9 colony-forming units (CFU) of *C. rodentium*, and pathogen load in feces (A) and mouse survival (B) were determined over the indicated time. Data points are means \pm SD. Results are representative of at least three independent experiments. ***P < 0.001, Mann-Whitney *U* test.

¹Department of Pathology and Comprehensive Cancer Center, The University of Michigan Medical School, Ann Arbor, MI 48109, USA. ²Division of Gastroenterology, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia V6H 3V4, Canada. ³Departamento de Microbiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos 62210, México. ⁴Department of Microbiology and Immunology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA.

^{*}To whom correspondence should be addressed. E-mail: bclx@umich.edu

(Fig. 3B). Consistent with these results, *ler-lux*expressing WT *C. rodentium* found attached to the cecal and colonic epithelium were abundant in the early phase of infection but dramatically decreased later during infection, even though pathogen burdens in the feces were comparable (Fig. 3C and fig. S12). These results indicate that the localization of the pathogen differs in the early and late phase of infection, and this is controlled by LEE virulence gene expression.

The intestine harbors a large number of bacterial species (18). To determine whether commensal bacteria exhibit different abilities to outcompete *C. rodentium*, we orally infected GF mice with *C. rodentium* and on day 21 post infection the mice were colonized with either *E. coli* or one of two different anaerobic *Bacteroides* species, all isolated from the intestines of SPF mice (19). The burden of *C. rodentium* in GF mice declined to \sim 1/200th by day 3 and to less than 1/500th by day 14 upon colonization with *E. coli*, but not at all with *B. thetaiotaomicron* or *B. vulgatus* (Fig. 4A). Secondary administration of *E. coli* to GF mice already colonized with *B. thetaiotaomicron* or or *S. thetaiotaomicron* or *S. thetaiotaomicron* or *B. vulgatus* (Fig. 4A).



Fig. 2. Expression and role of *ler* during *C. rodentium* infection in SPF and GF mice. (**A**) *ler* mRNA levels were determined by quantitative polymerase chain reaction in fecal pellets of SPF and GF mice infected with *C. rodentium* at the indicated days post infection. Expression was normalized to that of the kanamycin-resistance gene carried by the *C. rodentium* strain. Control experiments were performed by determining *ler* mRNA levels in *C. rodentium* grown under inducing Dulbecco's modified Eagle's medium (DMEM) and repressing Luria broth (LB) in vitro culture conditions (*4, 10*). Data represent mRNA expression relative to that in *C. rodentium* cultured in LB medium. Results are means \pm SD of individual mice (n = 3). Results are representative of at least two experiments. *P < 0.05, ***P < 0.001. (**B**) Expression of *ler* in fecal pellets of SPF and GF mice infected with the reporter *ler-lux C. rodentium* strain at the indicated day post infection. Results show luminescence (relative light units) and CFU of *ler-lux C. rodentium* in the same samples. Data are

expressed as means \pm SD of individual mice (n = 4). Results are representative of at least two experiments. (**C**) Bioluminescent imaging of *ler* expression in the intestines of SPF and GF mice infected with the *ler-lux C. rodentium* strain. Imaging was performed on day 5 and 14 post infection, and the signal was quantified on the basis of the color scale shown below. Results are representative of three individual mice. (**D**) SPF and GF mice (n = 5) were infected orally with 10° CFU of WT and $\triangle ler$ mutant *C. rodentium*, and pathogen load in feces was determined over the indicated time. Data points are means \pm SD. Results are representative of at least two experiments. (**E**) GF mice were infected with WT and $\triangle ler$ mutant *C. rodentium*. At day 3 or day 21 post infection, mice were cohoused with SPF mice (1:1). Pathogen load was determined in feces on the indicated days after cohousing. Dots represent individual mice. Results are representative of at least three experiments.

REPORTS

Fig. 3. Localization of C. rodentium to intestinal niches is mediated by LEE-encoded virulence factors. (A) Dual FISH staining with DNA probes that label virtually all true bacteria (EUB338, red) and the γ-Proteobacteria class to which C. rodentium belongs (GAM42a, green). Pathogenic bacteria (i.e., EUB338+/ GAM42a⁺ cells) are yellow. (Bottom) High-magnification images corresponding to boxed areas (top). Note the yellow color on all the bacteria stained in the cecum infected with the Δler mutant, which indicates that all bacteria in the lumen are C. rodentium. Scale bars: 50 μ m (top), 20 μ m (bottom). Results are representative of two experiments. (B) Transmission electron micrographs of cecum from infected GF mice at day 5 and day 21 post infection with WT C. rodentium and at day 5 with the Δler mutant. Original magnification: 3400× (left) and $13,500\times$ (right). Scale bars: 2 µm (left) and 500 nm (right). Results are representative of two experiments. (C) GF mice were infected orally with WT C. rodentium carrying the lerlux fusion. Cecum and colonic tissues were collected at the indicated day and then washed with phosphate-



buffered saline to remove nonadherent bacteria. Bioluminescent imaging of *ler* expression of *C. rodentium* attached to the cecum (top) and colon (bottom). Results are representative of two experiments using four different mice.

B. vulgatus also reduced the number of C. rodentium in the feces to $\sim 1/500$ th (Fig. 4A). In contrast, colonization of mice harboring E. coli with B. thetaiotaomicron or B. vulgatus was not effective in further reducing the burden of C. rodentium in their feces (Fig. 4A). Assessment of total Enterobacteria (E. coli and C. rodentium) and Bacteroides on day 14 post colonization with individual commensal bacteria showed comparable numbers of bacteria in the mouse feces (Fig. 4B). Before inoculation of commensal bacteria day 0 (d0), all Enterobacteria detected in the feces were C. rodentium (Fig. 4C). In contrast, >99% of the total Enterobacteria in the E. coli-inoculated group were E. coli after 14 days of colonization (Fig. 4C). We next analyzed the growth abilities of each of these species on a custom carbohydrate growth array that contains most of the common mono- and polysaccharides present in plant and animal tissue (Fig. 4D and table S1). Both C. rodentium and E. coli exhibited optimal growth

on monosaccharides (Fig. 4D). In contrast, both B. thetaiotaomicron and B. vulgatus exhibited broad abilities to catabolize both mono- and polysaccharides (Fig. 4D). Because y-Proteobacteria, such as E. coli, specifically accumulate after C. rodentium infection (7), these results suggest that this microbial change may benefit the host by increasing the number of commensals that can outcompete the pathogen. To further assess whether competition for glycans between commensals and C. rodentium is important for pathogen eradication, GF mice fed a conventional maintenance diet containing both mono- and polysaccharides were orally infected with C. rodentium, and on day 21 post infection, the infected GF mice were colonized with B. thetaiotaomicron for 7 days. On day 7 post colonization with B. thetaiotaomicron, the mice were divided into two groups that were fed the conventional diet or a simple sugar diet containing monosaccharides but not polysaccharides. The burden of C. rodentium in the GF mice

fed the simple sugar diet rapidly declined to ~1/200th by day 3, whereas no decline was observed when the mice were fed the conventional diet (Fig. 4E). The results were not explained by the simple sugar diet alone, because in the absence of colonization with B. thetaiotaomicron, the number of C. rodentium in feces was comparable between animals fed with the conventional and simple sugar diets (Fig. 4F). These results suggest that, while mice ingest the simple sugar diet, B. thetaiotaomicron cannot use polysaccharides and is forced to compete with C. rodentium for available monosaccharides or another common nutrient that both C. rodentium and B. thetaiotaomicron rely on in the absence of dietary polysaccharides. These findings clarify the tenuous nature of AE pathogens, in terms of their survival and/or colonization within hosts, and therefore, nutrient or probiotic shifting of the microbiota to promote commensals that directly compete with pathogens for food sources may be a useful therapeutic approach.

p/sec/cm²/sr) x10⁶



Diet C C C ss The formation of monosaccharides (MSs) or polysaccharides (PSs) indicated as representative of at least two experiments. (**D**) Carbohydrate catabolic profiles of *Cr* and commensal bacteria strains. Robust growth under supplementation of monosaccharides (MSs) or polysaccharides (PSs) indicated as red, and no growth indicated as yellow. Raw data are provided in table 51. (**E**) GF mice were infected with WT *Cr*. At day 21 post infection, *Bt* was inoculated. On day 7 post colonization with *Bt*, the mice were divided into two groups that were fed a conventional maintenance diet (C) or a simple sugar diet (ss). Pathogen load was determined in feces on day 3 after diet switching. Results are means \pm SD of individual mice (initially n = 10, and divided into two groups n = 5 each). Results are representative of two experiments. (**F**) *Cr* monoassociated GF mice (day 21) were fed a simple sugar diet (ssDiet) for 7 days. Pathogen load was compared before and after switching to ssDiet from conventional diet (cDiet). Dots represent individual mice and are representative of three independent experiments ***P* < 0.01. N.S. denotes not significant.

References and Notes

- J. B. Kaper, J. P. Nataro, H. L. Mobley, Nat. Rev. Microbiol. 2, 123 (2004).
- R. Mundy, T. T. MacDonald, G. Dougan, G. Frankel, S. Wiles, *Cell. Microbiol.* 7, 1697 (2005).
- W. Deng, Y. Li, B. A. Vallance, B. B. Finlay, *Infect. Immun.* 69, 6323 (2001).
- W. Deng et al., Proc. Natl. Acad. Sci. U.S.A. 101, 3597 (2004).
- 5. S. A. Luperchio et al., J. Clin. Microbiol. 38, 4343 (2000).
- D. Borenshtein, M. E. McBee, D. B. Schauer, Curr. Opin. Gastroenterol. 24, 32 (2008).
- 7. C. Lupp et al., Cell Host Microbe **2**, 204 (2007).
- 8. C. Hoffmann et al., Infect. Immun. 77, 4668 (2009).
- J. L. Mellies, S. J. Elliott, V. Sperandio, M. S. Donnenberg,
 B. Kaper, *Mol. Microbiol.* 33, 296 (1999).
- J. B. Kaper, Mol. Microbiol. 33, 296 (1999).
- 10. J. Barba *et al.*, *J. Bacteriol.* **187**, 7918 (2005).
- J. Bjarnason, C. M. Southward, M. G. Surette, J. Bacteriol. 185, 4973 (2003).
- H. S. Cooper, S. N. Murthy, R. S. Shah, D. J. Sedergran, *Lab. Invest.* 69, 238 (1993).

- 13. C. P. Simmons et al., Infect. Immun. **71**, 5077 (2003).
- 14. C. Maaser et al., Infect. Immun. 72, 3315 (2004).
- 15. L. Bry, M. B. Brenner, J. Immunol. 172, 433 (2004).
- 16. I. I. Ivanov et al., Cell 139, 485 (2009).
- 17. K. S. Bergstrom *et al.*, *PLoS Pathog.* **6**, e1000902 (2010).
- 18. J. Qin et al., Nature 464, 59 (2010).
- 19. S. M. Bloom et al., Cell Host Microbe 9, 390 (2011).

Acknowledgments: The authors thank the University of Michigan Germ-Free Animal Core, Microscopy and Image Analysis Laboratory, and the Center for Molecular Imaging for support; S. Koonse for animal husbandry; A. Huerta-Saquero for constructing the *pler-lux* plasmid; N. Pudlo for anaerobic bacteria culture; T. Stappenbeck for mouse commensal strains; J. Rousseau for technical assistance; and M. H. Shaw and G. Chen for expert review of the manuscript. BA.V. is the Canada Research Chair (Tier 2) in Pediatric Gastroenterology and the CH.I.L.D. Foundation Chair in Pediatric Inflammatory Bowel Disease Research. This work was supported by grants from the NIH, grants DK61707 and DK091191 (G.N.); Consejo Nacional de Ciencia y Tecnología, CONACyT (J.L.P.); Canadian Institutes of Health Research (B.A.V.); and the Uehara Memorial Foundation and Crohn's and Colitis Foundation of America Fellowship Awards (N.K). N.K. and G.N. hold U.S. provisional patent application no. 61/616,707 regarding inhibition of LEE virulence as a potential therapeutic for infection with AE pathogens. The data reported in this paper are tabulated in the main paper and in the supplementary materials.

Supplementary Materials

www.sciencemag.org/cgi/content/full/science.1222195/DC1 Materials and Methods Figs. S1 to S12 Table S1 References (20–22)

18 November 2011; accepted 30 March 2012 Published online 10 May 2012; 10.1126/science.1222195

Science

Regulated Virulence Controls the Ability of a Pathogen to Compete with the Gut Microbiota

Nobuhiko Kamada, Yun-Gi Kim, Ho Pan Sham, Bruce A. Vallance, José L. Puente, Eric C. Martens and Gabriel Núñez

Science **336** (6086), 1325-1329. DOI: 10.1126/science.1222195originally published online May 10, 2012

Establishing an Enteric Infection

Complex and highly regulated interactions are required to keep the peace between the bacteria that reside in our gut and the immune system. How do pathogenic bacteria, such as the strains of *Escherichia coli* that cause gastroenteritis, get a foothold to establish an infection, and what is the role of resident bacteria in this process? **Kamada** *et al.* (p. 1325, published online 10 May; see the Perspective by **Sperandio**) infected mice orally with *Citrobacter rodentium* and found that mice with normal commensal microflora, which were better able to contain the infection than mice that lacked the commensals, which were not able to clear the infection.

ARTICLE TOOLS	http://science.sciencemag.org/content/336/6086/1325
SUPPLEMENTARY MATERIALS	http://science.sciencemag.org/content/suppl/2012/05/09/science.1222195.DC1
RELATED CONTENT	http://science.sciencemag.org/content/sci/336/6086/1245.full http://science.sciencemag.org/content/sci/336/6086/1238.full
REFERENCES	This article cites 22 articles, 10 of which you can access for free http://science.sciencemag.org/content/336/6086/1325#BIBL
PERMISSIONS	http://www.sciencemag.org/help/reprints-and-permissions

Use of this article is subject to the Terms of Service

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science* is a registered trademark of AAAS.

Copyright © 2012, American Association for the Advancement of Science